Based on these results, this is the first finding that lunasin treatment might be beneficial in the inhibition of adipocyte inflammatory reactions through a decrease in IL-6 and MCP-1 secretions, and the retardation of obesity-related mediators that cause breast cancer cell metastasis, suggesting lunasin might block the cross-talk of these two cells. This evidence concerns the gene CCL2 and obesity disorder.